share_log

6-K: Truqap Improved rPFS in Advanced Prostate Cancer

6-K: Truqap Improved rPFS in Advanced Prostate Cancer

6-K:Truqap 改進了晚期前列腺癌的 RPF
美股SEC公告 ·  2024/11/25 11:57

牛牛AI助理已提取核心訊息

AstraZeneca's Phase III CAPItello-281 trial demonstrated that Truqap (capivasertib) in combination with abiraterone and ADT achieved statistically significant improvement in radiographic progression-free survival for PTEN-deficient metastatic hormone-sensitive prostate cancer patients. Early data showed a positive trend toward overall survival improvement, though results were not yet mature.The trial enrolled 1,012 adult patients with PTEN-deficient de novo mHSPC, targeting a specific subtype affecting approximately 25% of mHSPC patients. This marks the first successful application of an AKT inhibitor combination therapy in this particular form of prostate cancer, addressing a critical unmet need for patients with typically poor prognosis.The safety profile of the Truqap combination aligned with known characteristics of the component medicines. The trial will continue to assess overall survival as a key secondary endpoint, with data to be presented at an upcoming medical meeting and shared with global regulatory authorities.
AstraZeneca's Phase III CAPItello-281 trial demonstrated that Truqap (capivasertib) in combination with abiraterone and ADT achieved statistically significant improvement in radiographic progression-free survival for PTEN-deficient metastatic hormone-sensitive prostate cancer patients. Early data showed a positive trend toward overall survival improvement, though results were not yet mature.The trial enrolled 1,012 adult patients with PTEN-deficient de novo mHSPC, targeting a specific subtype affecting approximately 25% of mHSPC patients. This marks the first successful application of an AKT inhibitor combination therapy in this particular form of prostate cancer, addressing a critical unmet need for patients with typically poor prognosis.The safety profile of the Truqap combination aligned with known characteristics of the component medicines. The trial will continue to assess overall survival as a key secondary endpoint, with data to be presented at an upcoming medical meeting and shared with global regulatory authorities.
阿斯利康的III期CAPItello-281試驗表明,Truqap(卡匹伐替尼)與阿比特龍和ADt聯合使用在PTEN缺乏的轉移性荷爾蒙敏感前列腺癌患者中顯著改善了放射學進展無生存期。早期數據顯示整體生存改善的趨勢積極,但結果尚未成熟。該試驗共招募了1,012名PTEN缺乏的原發性轉移性荷爾蒙敏感前列腺癌成年患者,針對約佔mHSPC患者25%的特定亞型。這標誌着在這種特定類型的前列腺癌中首次成功應用AKt抑制劑聯合治療,滿足了患者對通常預後較差的重大未滿足需求。Truqap聯合治療的安全性與組成藥物的已知特性一致。試驗將繼續評估整體生存作爲一個關鍵的次要終點,數據將在即將舉行的醫療會議上公佈,並與全球監管機構分享。
阿斯利康的III期CAPItello-281試驗表明,Truqap(卡匹伐替尼)與阿比特龍和ADt聯合使用在PTEN缺乏的轉移性荷爾蒙敏感前列腺癌患者中顯著改善了放射學進展無生存期。早期數據顯示整體生存改善的趨勢積極,但結果尚未成熟。該試驗共招募了1,012名PTEN缺乏的原發性轉移性荷爾蒙敏感前列腺癌成年患者,針對約佔mHSPC患者25%的特定亞型。這標誌着在這種特定類型的前列腺癌中首次成功應用AKt抑制劑聯合治療,滿足了患者對通常預後較差的重大未滿足需求。Truqap聯合治療的安全性與組成藥物的已知特性一致。試驗將繼續評估整體生存作爲一個關鍵的次要終點,數據將在即將舉行的醫療會議上公佈,並與全球監管機構分享。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。